Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients

Journal of Surgical Research

Volumn 178, Issue 1, 2012, Pages 288-293

  Valadão, Marcus ^a   Braggio, Danielle ^a   Santos, Anna Flávia ^a   Pimenta Inada, Haynna Kimie ^a   Linhares, Eduardo ^a   Gonçalves, Rinaldo ^a   Romano, Sérgio ^a   Vilhena, Bruno ^a   Small, Isabele ^a   Cubero, Daniel ^b   Cruz, Felipe ^b   Oliveira, Antônio Talvane ^c   Martinho, Olga ^d   Reis, Rui Manuel ^c,d   Guimarães, Denise Peixoto ^a,c   Ferreira, Carlos Gil ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FACULDADE DE MEDICINA DO ABC   (Brazil)

^c Barretos Cancer Hospital   (Brazil)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

GIST; IGF; Imatinib mesylate; Metastatic; Prediction; Response

Indexed keywords

IMATINIB; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN KINASE C THETA; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR CROSS-TALK; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84868194683     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2012.03.031     Document Type: Article

References (27)

1. R.P. DeMatteo, J.J. Lewis, and D. Leung Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival Ann Surg 231 2000 51
2. E.H. Ng, R.E. Pollock, and M.F. Munsell Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 1992 68
3. H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052
4. M.C. Heinrich, C.L. Corless, and G.D. Demetri Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342
5. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial Lancet 364 2004 1127
6. B. Rubin, M. Heinrich, and C. Corless Gastrointestinal stromal tumour Lancet 369 2007 1731
7. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626
8. C.R. Antonescu, P. Besmer, and T. Guo Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 2005 4182
9. A.W. Gramza, C.L. Corless, and M.C. Heinrich Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors Clin Cancer Res 15 2009 7510
10. T. Negri, G.M. Pavan, and E. Virdis T670X KIT mutations in gastrointestinal stromal tumors: Making sense of missence J Natl Cancer Inst 101 2009 194
11. C. Corless, J. Fletcher, and M. Heinrich Biology of gastrointestinal stromal tumors J Clin Oncol 22 2004 3813
12. C. Tarn, L. Rink, and E. Merkel Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors Proc Natl Acad Sci U S A 105 2008 8387
13. N.P. Agaram, M.P. Laquaglia, and B. Ustun Molecular characterization of pediatric gastrointestinal stromal tumors Clin Cancer Res 14 2008 3204
14. A. Duensing, N.E. Joseph, and F. Medeiros Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs) Cancer Res 64 2004 5127
15. M.J. Zhu, W.B. Ou, and C.D. Fletcher KIT oncoprotein interactions in gastrointestinal stromal tumors: Therapeutic relevance Oncogene 26 2007 6386
16. J. Klysik, S.J. Theroux, and J.M. Sedivy Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction Cell Signal 20 2008 1
17. O. Martinho, A. Gouveia, and P. Silva Loss of RKIP expression is associated with poor survival in GISTs Virchows Arch 455 2009 277
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205
19. D.P. Guimaraes, I.M. Oliveira, and G.R. Paiva Interferon-inducible guanylate binding protein (GBP)-2: A novel p53-regulated tumor marker in esophageal squamous cell carcinomas Int J Cancer 124 2009 272
20. C. Raut, M. Posner, and J. Desai Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2006 2325
21. R. DeMatteo, R. Maki, and S. Singer Results of kinase inhibitors therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 2007 347
22. A. Gronchi, M. Fiore, and F. Miselli Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 2007 341
23. C. Braconi, R. Bracci, and I. Bearzi Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients Ann Oncol 19 2008 1293
24. E. Braggio, D. Braggio, and I. Small Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors Anticancer Res 30 2010 2407
25. M. VanGlabbeke, J. Verwiej, and J.Y. Blay Comparasion of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) J Clin Oncol 28 2010 1247
26. H. Choi, C. Charnsangavej, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753
27. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760